{"chunk_type":"transcript_chunk","text":"# Sickle Cell Disease: Core Pathophysiology and Early Crisis Framework\n## Molecular core\n- Beta-globin mutation (Glu -> Val) creates HbS with hydrophobic polymerization tendency under deoxygenated stress.\n- Sickling is promoted by hypoxia, dehydration, and acidosis.\n- Downstream effects: vaso-occlusion + hemolysis.\n\n## High-yield architecture\n```\nSCD\n├── Genetics/electrophoresis interpretation\n├── Acute crises: pain, ACS, sequestration, aplastic crisis, stroke\n└── Prevention: HbF induction, infection prophylaxis, stroke screening\n```\n\n## Electrophoresis logic\n| Pattern | HbA | HbS | Clinical implication |\n| --- | --- | --- | --- |\n| Normal | predominant | absent | no sickling disease |\n| Trait (HbAS) | present | present | usually mild; renal papillary issues may occur |\n| Disease (HbSS) | absent | predominant | severe phenotype with recurrent crises |\n\n## Vaso-occlusive pain crisis\n- Includes dactylitis in infants/young children.\n- Management pillars: hydration + analgesia.\n\n## VOC vs osteomyelitis bedside distinction\n| Feature | VOC | Osteomyelitis |\n| --- | --- | --- |\n| Distribution | often multifocal pain/swelling | often focal site |\n| Fever pattern | lower-grade possible | persistent higher fever common |\n| Primary management focus | pain/hydration support | targeted antibiotics ± surgical evaluation |","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-130","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Sickle Cell Emergencies: ACS, Splenic Sequestration, Aplastic Crisis, Stroke\n## General acute pain crisis management\n- Hydration, adequate analgesia (opioids when severe), oxygen only if hypoxemic.\n- Transfusion is complication-specific, not routine for every pain episode.\n\n## Acute chest syndrome (major mortality driver)\n- New infiltrate on CXR plus fever/respiratory symptoms.\n- Triggers include infection and fat embolic physiology depending on age/context.\n- Treatment: oxygen support, broad antibiotics (including atypical coverage), pain control, fluids, and simple/exchange transfusion when severe.\n\n## Splenic sequestration\n- Child with sudden pallor, lethargy, splenomegaly, shock risk.\n- Reticulocyte count typically elevated.\n- Management: urgent volume resuscitation + transfusion; recurrent severe episodes may lead to splenectomy pathway.\n\n## Aplastic crisis vs sequestration trap\n| Feature | Aplastic crisis | Splenic sequestration |\n| --- | --- | --- |\n| Typical cause | Parvovirus B19 marrow suppression | splenic trapping of blood |\n| Reticulocytes | low | high |\n| Spleen size | often not massively enlarged | enlarged |\n\n## Stroke pathway\n- Pediatric TCD screening identifies high-risk velocities.\n- Acute stroke management emphasizes exchange transfusion strategy and long-term prevention transfusion planning.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-150","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"# Sickle Cell Chronic Organ Burden, Maintenance, and Pregnancy\n## Chronic complications\n- Pulmonary vascular disease and right-heart strain.\n- Renal concentrating defects and papillary injury/hematuria patterns.\n\n## Maintenance bundle\n1. Hydroxyurea to increase HbF and reduce vaso-occlusive burden.\n2. Pediatric penicillin prophylaxis through early childhood.\n3. Vaccination against encapsulated organisms plus routine influenza protection.\n\n## Pregnancy in SCD\n- Elevated risk for fetal growth restriction, preeclampsia, and pregnancy loss complications.\n- Requires high-risk obstetric monitoring and serial fetal growth assessment.\n\n## Rapid clinical recap\n- Massive spleen + shock + high retic -> sequestration.\n- Severe anemia + low retic -> aplastic crisis (often parvovirus context).\n- Fever/chest pain/new infiltrate -> acute chest syndrome pathway.\n- SCD osteomyelitis: Salmonella is high-yield association (while Staph remains common overall).\n- Painless hematuria in otherwise healthy carrier profile -> trait-associated papillary injury pattern.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-170","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Hemolytic Anemia and Heme Synthesis: Structured Map\n## Classification map\n```\nAnemia (reticulocyte-high branch)\n├── Intrinsic hemolysis\n│   ├── Membrane defects (for example hereditary spherocytosis)\n│   ├── Enzyme defects\n│   └── Hemoglobin defects\n├── Extrinsic hemolysis\n│   ├── Mechanical destruction (for example prosthetic valve)\n│   └── Immune-mediated forms\n└── Heme synthesis disorders\n    ├── Acute intermittent porphyria\n    └── Lead toxicity differential\n```\n\n## Hereditary spherocytosis core\n- Spectrin/ankyrin-related membrane instability -> spherocyte formation -> splenic trapping/extravascular hemolysis.\n- Typical clues: jaundice, splenomegaly, family history, pigment gallstones.\n- Distinguish from AIHA with Coombs test (HS is Coombs-negative).\n- Common supportive findings: elevated MCHC and positive fragility/EMA-related tests.\n- Definitive management in selected patients: splenectomy pathway.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-190","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# Mechanical Valve Hemolysis and Acute Intermittent Porphyria (AIP)\n## Mechanical valve hemolysis\n- Prosthetic/paravalvular turbulence creates shear stress with intravascular RBC fragmentation.\n- Clues: fatigue, dark urine, schistocytes, hemolysis labs.\n- Next diagnostic step: echocardiographic assessment of valve function/leak.\n\n## AIP pattern\n- Enzyme defect in porphyrin pathway (porphobilinogen deaminase) with ALA/PBG accumulation.\n- Classic triad cluster: severe abdominal pain (often soft abdomen), neuropsychiatric symptoms, neuropathy; urine may darken/port-wine.\n- Common precipitants: CYP-inducing drugs, alcohol, fasting/starvation.\n- Acute treatment principle: suppress pathway activation with glucose and hemin.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-210","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# AIP vs Lead Poisoning Differential + Scenario Recap\n## Differential table\n| Feature | AIP | Lead poisoning |\n| --- | --- | --- |\n| Blocked enzyme zone | porphobilinogen deaminase pathway | ALA dehydratase/ferrochelatase inhibition |\n| Key accumulated intermediates | ALA + PBG | ALA predominance (PBG not similarly elevated) |\n| Smear clue | usually no lead-specific stippling | basophilic stippling |\n| Additional clue | neurovisceral attacks, darkening urine episodes | Burton line and toxic exposure context |\n\n## Rapid scenarios\n1. Child with anemia+splenomegaly+jaundice+Coombs negative -> hereditary spherocytosis.\n2. Mechanical valve patient with dark urine/schistocytes -> assess valve by echocardiography.\n3. Severe abdominal pain + psych symptoms + soft abdomen -> consider AIP, treat acute attack with glucose/hemin.\n4. Neuropathy + abdominal pain + basophilic stippling -> lead toxicity pathway.\n5. In AIP attacks, identify and remove precipitating triggers (alcohol/fasting/inducing drugs).","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-230","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Leukemia Big Picture and Acute Leukemia Entry\n## Acute vs chronic framing\n| Axis | Acute leukemia | Chronic leukemia |\n| --- | --- | --- |\n| Tempo | rapid, sick presentation | slower, often incidental |\n| Cell pattern | blast-predominant (>20% in marrow) | mature-cell predominance |\n| Typical urgency | oncologic emergency behavior | staged risk-directed management |\n\n## Main entities\n- Acute: ALL, AML.\n- Chronic: CML, CLL, Hairy cell leukemia.\n\n## Pediatric acute leukemia doorway\n- Child with bone pain/refusal to walk + fever + cytopenias should trigger leukemia workup.\n- Marrow blast expansion causes pain and normal hematopoiesis failure (anemia, thrombocytopenia, neutropenia).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-1","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"# ALL, CML, CLL, Hairy Cell Leukemia: High-Yield Distinctions\n## Entity comparison\n| Entity | Typical profile | Hallmark clues | Core management anchor |\n| --- | --- | --- | --- |\n| ALL | childhood-predominant acute leukemia | marrow blasts, possible mediastinal mass in T-cell subtype, sanctuary-site concern (CNS/testes) | marrow-confirmed protocol therapy with CNS/testicular attention |\n| CML | chronic myeloid proliferation in adults | very high WBC, basophilia, splenomegaly, BCR-ABL fusion | tyrosine kinase inhibitor pathway |\n| CLL | older adults, often indolent | lymphocytosis, smudge cells, immune dysfunction/autoimmune complications | watchful waiting vs treatment by symptom/progression risk |\n| Hairy cell leukemia | middle age with splenic predominance | cytopenias, dry tap tendency, hairy morphology/TRAP profile, minimal adenopathy | purine analog therapy (for example cladribine) |\n\n## Practical notes\n- CML-vs-leukemoid differentiation uses clinical context plus LAP/basophil and molecular patterns.\n- CLL can transform aggressively (Richter transformation) and needs surveillance for that shift.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-21","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# Rapid Recap: Leukemia and Transition to Survivorship/Plasma Cell Disorders\n## Leukemia recap\n1. Child refusing to walk with pancytopenia -> evaluate ALL with marrow confirmation and sanctuary-site strategy.\n2. Teen with mediastinal mass/SVC pattern -> consider T-cell ALL.\n3. Adult with very high WBC + basophilia + low-LAP context -> evaluate CML/BCR-ABL and treat with targeted TKI.\n4. Elderly asymptomatic lymphocytosis + smudge cells -> CLL; monitor for transformation.\n5. Massive splenomegaly + dry tap + hairy morphology -> hairy cell leukemia.\n\n## Next framework introduced\n- Long-term Hodgkin survivor risk transition from relapse-dominant to treatment-related secondary disease.\n- Plasma cell dyscrasia branch contrasts Multiple Myeloma (CRAB/lytic) with Waldenstrom macroglobulinemia (IgM hyperviscosity).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-41","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic","tree"]}
{"chunk_type":"transcript_chunk","text":"# Hodgkin Survivorship and Plasma Cell Dyscrasia Comparison\n## Hodgkin survivorship timeline\n- Early years after therapy: relapse risk remains key.\n- Later years (especially >15 years): secondary malignancy and treatment-related cardiovascular disease become dominant concerns.\n- Surveillance targets include prior radiation fields (lung/breast/thyroid etc.) and cardiotoxic/radiation-associated heart disease.\n\n## Alcohol-related node pain pearl\n- Rare but classically associated clinical clue in Hodgkin context.\n\n## Plasma cell dyscrasia split\n| Feature | Multiple myeloma | Waldenstrom macroglobulinemia |\n| --- | --- | --- |\n| Dominant immunoglobulin | usually IgG/IgA | IgM pentamer |\n| Primary damage mode | bone lysis + renal injury | hyperviscosity syndrome |\n| Typical manifestations | CRAB spectrum, bone pain/fracture | blurry vision, mucosal bleeding, hepatosplenomegaly |\n\n## Myeloma anchor\n- Osteoclast activation drives lytic lesions and hypercalcemia pathway.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-61","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Waldenstrom and the Myeloma Imaging Trap\n## Waldenstrom core\n- IgM macroprotein elevates serum viscosity causing visual symptoms, bleeding tendency, and organ congestion.\n- Bone lytic lesions are typically absent compared with myeloma.\n\n## Critical imaging trap in myeloma\n- Nuclear bone scan can miss purely lytic disease because it depends on osteoblastic activity.\n- Preferred evaluation is skeletal survey or low-dose whole-body CT for punched-out lytic lesions.\n\n## Practical exam rule\n- Suspected myeloma bone disease + negative bone scan does not exclude disease; choose lytic-lesion-focused imaging modality.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-81","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Hodgkin Survivorship, Myeloma, Waldenstrom\n| Condition | Key mechanism | Key clue | Next-step anchor |\n| --- | --- | --- | --- |\n| Post-treatment Hodgkin survivorship | treatment-related late toxicity | new malignancy/CVD risk rises long-term | targeted secondary-cancer and cardiac surveillance |\n| Active Hodgkin clue | nodal process | alcohol-induced nodal pain (rare but specific) | formal lymphoma workup/staging |\n| Multiple myeloma | plasma-cell osteoclast activation + monoclonal burden | CRAB + lytic bone pain | skeletal survey/whole-body CT and myeloma workup |\n| Waldenstrom | IgM-driven hyperviscosity | blurry vision, bleeding, organ congestion | viscosity-focused treatment path (plasmapheresis when symptomatic) |\n| Imaging trap | osteoblastic-scan mismatch | normal bone scan despite myeloma symptoms | avoid bone scan as sole test for lytic disease |\n\n## Cleanup\n- Removed non-learning conversational/apology text and retained only exam-relevant medical summary.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-93","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","pathophysiology"]}
